O slideshow foi denunciado.
Seu SlideShare está sendo baixado. ×

Polysaccharide Hydrogels: a versatile tool for biomedical and pharmaceutical applications.

Carregando em…3

Confira estes a seguir

1 de 64 Anúncio

Mais Conteúdo rRelacionado

Diapositivos para si (19)

Semelhante a Polysaccharide Hydrogels: a versatile tool for biomedical and pharmaceutical applications. (20)


Mais de Sociedade Brasileira de Pesquisa em Materiais (20)

Mais recentes (20)


Polysaccharide Hydrogels: a versatile tool for biomedical and pharmaceutical applications.

  1. 1. Polysaccharide hydrogels: a versatile tool for biomedical and pharmaceutical applications Department of Drug Chemistry and Technologies Sapienza University of Rome Rome, Italy Pietro Matricardi XVII Brazil MRS Meeting September,16th -20th, 2018 Natal
  2. 2. Hydrogels for food “molecular cuisine”
  3. 3. Hydrogels for personal care
  4. 4. Hydrogels for health and wellness
  5. 5. Hydrogels for pharma
  6. 6. The colloid condition, the gel, is one which is easier to recognize than to define Dorothy Jordan Lloyd (1926) Or, in other words, “if it looks Jello, it must be a gel” What is a hydrogel
  7. 7. • Like a “fourth state” of matter ü polymer network (10-20%) and water ü the concepts of solute and solvent from a “classical” thermodynamic point of view are unable to describe the system • Depending on its nature: ü self sustaining under its own weight ü able to shear under the action of a stress Some characteristics
  8. 8. Hydrogel network structures Based on polymers Chemical hydrogels Physical hydrogels reversible crosslinks covalent crosslinks
  9. 9. 10 From a rheological point of view (Ross-Murphy and Burchard): viscoelastic behaviour Solution Strong gel Weak gel
  10. 10. Polysaccharides ü Most of them are abundant in nature (commodities or mass-market products) ü Readily available from renewable sources (algal and plant kingdoms, cultures of microbial selected strains, recombinant DNA techniques) ü Large variety of compositions and properties ü Biocompatible (food, medical device or pharma applications) ü Often cheaper than synthetic polymers ü Favourable chemical and physico-chemical properties due to the wide variety of functional groups, macromolecular architecture and molecular weights
  11. 11. Dextran Gellan Gum Guar Gum Locust Bean Gum Hyaluronic acid Alginate Xanthan Gum Scleroglucan SOME POLYSACCHARIDES
  12. 12. As “inert” drug carrier in conventional formulations: • Filler (bulk formulation) • Film forming (tablets or capsules) • Viscosity agent in liquid formulations
  13. 13. Hydrogels & Polysaccharides
  14. 14. Ionotropic gelation Chemical cross-linking Calcium alginate hydrogels Dextran methacrylate hydrogels
  15. 15. Hydrogels & Polysaccharides
  16. 16. Drug and Protein Delivery Tissue Engineering
  17. 17. Bulk hydrogel Nano hydrogel
  19. 19. HYDROGEL FOR DENTAL APPLICATIONS üComplete filling of confinedspaces, such as gum pockets üAble to carry q Drugs q Biologically Active Substances üThe gel adheres to soft tissues due to the film-formingproperties of one of the polymer component üObtained by means of ionotropic gelation so no chemical reactionsare involved nor toxic substances are formed as byproducts
  20. 20. IONOTROPIC GELATION Ions Synthetic polymer Polysaccharide
  21. 21. To improve bone growth for implant On the market Ø Homologous bone - animal derived products - synthetic bone Ø Osteocompatible resins Pilot study #1 - Hydroxyapatite
  22. 22. ü Treatement of severe periodontitis ü Cleaning of the pocket by curette ü Applications of the drug loaded-hydrogel ü New implant after 8 weeks Pilot study #2 - nimesulide NB BM n-MT NB NB n-MT BM NB Ematossilina-Eosina 4X % n-MT (non-Mineralized Tissue): 65% % BM (Biomaterial): 5% % NB (New Bone): 30%
  23. 23. üFilling effect üPain relief (with and without drug) in all patiences üHydrogel resorption in 4 weeks and promotion of new bone formation Results
  24. 24. Hydrogel for heritage protection Stone materials and Biodeterioration
  25. 25. ü Cleaning and protection of stone materials ü Bio-colonization ü Organic solvent-free product Why polysaccharide hydrogels Italy possesses a huge heritage (45% of the world cultural heritage?!?!?)
  26. 26. Surface Hydrogel on the surface After film removal
  27. 27. Duchessa di Genova (1900) by Pietro Canonica
  28. 28. Polysaccharide nanohydrogels for drug delivery applications
  29. 29. Drug Delivery – Controlled release Polymeric nanoparticle Liposome dendrimer Inorganic nanoparticle “MAGIC BULLET” A substance or therapy capable of destroying pathogenic agents (as bacteria or cancer cells) or providing a remedy for a disease or condition without deleterious side effects, by specifically targeting the diseased tissue Dr. Paul Ehrlich Solid Lipid Nanoparticle Nanogels Nanoscale hydrogels
  30. 30. POLYSACCHARIDE-BASED NANOHYDROGELS SELF-ASSEMBLING IN WATER HYDROPHOBIC MOIETY POLYSACCHARIDE ü Nanosized hydrogels (150-300 nm) ü Nanoparticulate drug carriers ü High water content ü High biocompatibility ü Mucoadhesive properties gellan gum or hyaluronan prednisolone cholesterol riboflavin derivatives
  31. 31. HYDROPHOBIC MOIETY POLYSACCHARIDE CRYO-TEM micrographs Optical image 10 µm 100 nm 50 nm * new patented method AFM image by several approaches POLYSACCHARIDE-BASED NANOHYDROGELS
  32. 32. (121°C, 1.10 bar, 20 min) 1) preparation of sterile NHs 2) Reduction of the NHs polydispersity 3) Simultaneous formation, loading* and sterilization of NHs HYDROPHOBIC MOIETY POLYSACCHARIDE Autoclave treatment * * new patented method: • WO2014199318 (A2) ― 2014-12-18 MC De Rugeriis, E. Montanari, C. Di Meo, P. Matricardi - METHOD FOR PREPARING NANOHYDROGELS • WO2014199319 (A2) ― 2014-12-18 G. D’Arrigo, C. Cencetti, C. Di Meo, P. Matricardi - METHOD FOR THE TREATMENT OF NANOHYDROGELS An innovative method for sterile polysaccharide NHs production Cryo -TEM 100 nm Autoclave 121°C 1.10 bar, 20 min * For thermo-stable drugs polymerdrug Co-suspension in water Film-casting technique drug film polymer suspension
  33. 33. Long-term storage 0 50 100 150 NHs before freeze- drying NHs + dextrose before freeze-drying NHs + dextrose after freeze-drying d (nm) 0 0.2 0.4 0.6 0.8 1 PDI diameter PDI E. Montanari, M.C. De Rugeriis, C. Di Meo, R. Censi, T. Coviello, F. Alhaique, P. Matricardi Journal of Materials Science: Materials in Medicine , 2015,26:32 Freeze-drying
  34. 34. HACH HARfv NHs self assembly ~ 200 - 300 nm (hydrophobic interactions) Autoclave 20 min 121 °C CAC = 134 µg/mL scattering intensity mean size scattering intensity mean size CAC = 235 µg/mL NHs properties
  35. 35. ü Stability Denaturating agent: urea Dilution test 37
  36. 36. HACH NHs Dry conditions SWELLING RATIO ü Atomic Force Microscopy Wet conditions Dry conditions:TAPPING MODE (Substrate: mica + MgCl₂ 10mM) Wet conditions:CONTACTMODE/ScanAsyst® (Substrate: Si 1,0,0 derivatised with APTES((3-amminopropil)-trietossisilane)
  37. 37. NHs HACH NHs HARfv Mean diameter 330 ± 20 nm 180 ± 24 nm PDI 0.120 ÷ 0.250 0.100 ÷ 0.200 ζ Potential -46.7 ± 1.8 mV -40.5 ± 4.5 mV Q: swelling ratio 6200 4400 Young Modulus 108 KPa 610 KPa Fluorescence No Yes
  38. 38. hydrophilic drug hydrophobic drug empty NHs Loading within hydrophilic domains Loading within hydrophobic domains Loaded molecules Paclitaxel Levofloxacin Piroxicam Dexamethasone DRUGS NATURAL SUBSTANCES Curcumin Resveratrol Annona extracts PROTEINS BSAO by nanoprecipitation, autoclave treatment, solvent casting…. ALGINATE LYASE Highly versatile drug carriers
  39. 39. Gellan-prednisolone (Ge-pred) and Gellan-cholesterol (Ge-CH) NHs for dual drugs therapy
  40. 40. Advantages: ü Prednisolone is already clinically used in combination with chemotherapeutics in several anticancer protocols (e.g. prostate cancer) to prevent or reduce side effects. ü Inflammation contributes to tumor initiation, induces proliferation of malignant cells, enhances their survival, and stimulates angiogenesis and metastatic spread. ü Cancer, in turn, takes advantage of inflammatory mediators to grow, thereby generating an inflammatory microenvironment in tumors for which there is no underlying inflammatory condition. Paclitaxel (PCT) Prednisolone
  41. 41. Mw reduction by Ultrasonication Sonication time Mw/Mn Sonication time1 3 2 4 5 1 3 2 4 5 1 3 2 4 5 1 32 4 5 6 6’ 6 6’ -CH3 1.40 1.30 1.20 18 20 22 ppm Gellan Gum Glc Glc haGlc GPC ü Mw reduction of gellan by probe ultrasonication 1 H-13 C HSQC NMR map
  42. 42. ü Synthesis of polymer derivatives Same steps with cholesterol (dd = 10%) derivatization degree (dd) = 10% m/m yield = 50% ü NHs formation and stability PREDNISOLONE or CHOLESTEROL GELLAN GUM nanoprecipitation ultrasound treatment or 25°C
  43. 43. ü Cell biocompatibility G. D'Arrigo, C. Di Meo, E. Gaucci, S. Chichiarelli, T. Coviello, D. Capitani, F. Alhaique, P. Matricardi Soft Matter 2012, 8, 11557 Fibroblast Heart myoblast Prostate cancer
  44. 44. ü Anti-inflammatory activity
  45. 45. • Paclitaxel loading into Ge-pred and Ge-CH NHs by solvent casting technique • Paclitaxel concentration reached in NHs suspension = 140 µg/mL (free Paclitaxel in water = 0.1 µg/mL) Paclitaxel (PCT) Prednisolone ü Loading with anticancer drug PCT release in vitro PC-3 cells, 72h PCT 3 nM
  46. 46. IC50 Paclitaxel: 33.7 nM Paclitaxel in NHs: 15.1 nM Paclitaxel in NHs + Prednisolone: 7.7 nM G. D'Arrigo, G. Navarro, C. Di Meo, P. Matricardi, V. Torchilin, European Journal of Pharmaceutics and Biopharmaceutics 2014, 87, 208 Skov-3 cell line Anticancer activity of PCT-loaded NHs
  47. 47. Hyaluronan-cholesterol (HA-CH) NHs for antibiotic delivery
  48. 48. A new challenge
  49. 49. • Antibiotic resistance due to the intracellular escape (for facultative or obligate pathogens) • Levofloxacine: poorly effective against intracellular bacteria (efflux pump) Levofloxacin
  50. 50. • Levofloxacin loading into HA-CH NHs by autoclave technique • Levofloxacin concentration reached in NHs suspension = 12 ± 1 % w/w • Antibacterial activity against S. Aureus and P. Aeruginosa strains • Cell (HeLa) infection by S. Aureus and P. Aeruginosa and treatment with free LVF and LVF-loaded NHs Levofloxacin MIC values of Levoflloxacin (LVF) and NH-encapsulated Levofloxacin (NH-LVF) on S. aureus ATCC6538P, S.aureus USA300-0114 and P. aeruginosa PAO-1. Comparable MIC E. Montanari, G. D’Arrigo, C. Di Meo, A. Virga, T. Coviello, C. Passariello, P. Matricardi. Eur. J. of Pharmaceutics and Biopharmaceutics, 2014, 87, 518
  51. 51. FREE LVF: no significant activity on intracellular bacteria Activity of LVF and NH-LVF (both freshly prepared and resuspended after freeze-drying) on intracellular P. aeruginosa PAO-1 and S. aureus USA 300-0114. LVF-NHs: > 90% eradication of intracellular bacteria
  52. 52. Levofloxacin Gentamicin Topical applications
  53. 53. • Levofloxacin (LVF) and gentamicin(GM) loading into HA-CH NHs • Antiibacterial activity against S. Aureus • Human keratinocites (HaCaT) infection by S. Aureus and treatment with free LVF and GM drug-loaded NHs
  54. 54. Scheme of the intracellular fate of free GM, LVF and their nanoformulations in S. aureus-infected keratinocytes. E. Montanari, A.Oates, C. Di Meo, J. Meade, R. Cerrone, A. Francioso, S. Devine, T. Coviello, P. Mancini, L. Mosca and P. Matricardi Adv. Healthcare Mater. 2018, 1701483
  55. 55. Topical applications of NHs
  56. 56. Topical applications of NHs -1 Piroxicam Ge-CH Ge-Rfv U.M. Musazzi, C. Cencetti, S. Franzé, N. Zoratto, C. Di Meo, P. Procacci, P. Matricardi, F. Cilurzo, Mol. Pharmaceutics 2018, 15, 1028−1036
  57. 57. Baicalin Ge-CH M. Manconi, M.L. Manca C. Caddeo, C. Cencetti, C. Di Meo, N. Zoratto, .. P. Matricardi Eur. J. Pharm. Biopharm. 2018, 127, 244–249 Topical applications of NHs -2
  58. 58. Other applications ü NHs in aesthetic surgery ü Antioxidant for cardiovascular applications ü Anti-inflammatory-loaded NHs for the treatment of primary sclerosing cholangitis ü NHs formulations for ocular applications ü HA-based NHs in cosmetics
  59. 59. Special thanks to: Franco Alhaique Tommasina Coviello Chiara Di Meo Elita Montanari Nicole Zoratto
  60. 60. Thank you for your kind attention